This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Congenital Nephrotic Syndrome, Minimal Change Disease최소변화병변 선천성 신증후군 (최소변화병변 선천성신증후군)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: N04.0 (congenital nephrotic syndrome with minor glomerular abnormality/minimal change lesion) | Special Copayment Reduction: V263 (rare disease)
B. SynonymsCongenital nephrotic syndrome with minor glomerular abnormality | Congenital nephrotic syndrome with minimal change lesion
C. Adult onsetLikelihood of first onset in adulthood very low — by definition, congenital nephrotic syndrome presents within 3 months after birth (within 1 year in some classifications), and most patients are diagnosed in the neonatal period or early infancy. An asymptomatic course into adulthood is extremely rare, and even when diagnosis is delayed, symptoms are clearly evident in childhood.
1. History1956: congenital nephrotic syndrome of the Finnish type (CNF) described by Hallman → NPHS1 (nephrin) cloned in 1998 → elucidation of the molecular mechanism of minimal change congenital nephrotic syndrome under way
2. CausesVariants in glomerular filtration barrier-related genes such as NPHS1 (nephrin), NPHS2 (podocin), WT1, LAMB2, and PLCE1; minimal change type is normal on light microscopy but shows foot process effacement on electron microscopy
3. GeneticsMostly autosomal recessive (AR); NPHS1 19q13.12, NPHS2 1q25.2, WT1 11p13, LAMB2 3p21; genotype-phenotype correlations partly established
4. General epidemiologyOverall incidence of congenital nephrotic syndrome about 1–2 per 10,000 births; minimal change type is a minority; high frequency of NPHS1 variants in the Finnish population
5. PathophysiologyAbnormal nephrin-podocin complex → collapse of the slit diaphragm structure of the glomerular filtration barrier → massive proteinuria → hypoalbuminemia → edema
6. SymptomsOnset within 3 months after birth; generalized edema, ascites, pleural effusion, hypoalbuminemia, massive proteinuria; malnutrition, increased susceptibility to infection
7. SignsGeneralized edema (face, limbs, abdomen), ascitic distension, growth retardation, hypoproteinemia, hyperlipidemia, positive urine protein (>40 mg/m²/hr)
8. ScreeningNewborns with a family history: urine protein testing, serum albumin measurement; gene panel testing (NPHS1, NPHS2, etc.)
9. DiagnosisConfirmed by urine protein/creatinine ratio, kidney biopsy (light and electron microscopy), immunofluorescence, and gene panel testing
10. TreatmentPoor steroid response is common; immunosuppressants (cyclophosphamide, cyclosporine, tacrolimus); ACE inhibitors/ARBs; nutritional support; kidney transplantation is the definitive treatment
11. PrognosisMostly steroid-resistant; frequent progression to end-stage renal disease; possible post-transplant recurrence; anti-nephrin antibodies may form after transplantation with NPHS1 variants
12. PreventionGenetic counseling for carrier parents; preimplantation and prenatal genetic testing; pre-transplant antibody monitoring
13. References10 key references (with PMID or DOI)

1. History

The history of congenital nephrotic syndrome (CNS) began in 1956 when the Finnish pediatrician Martti Hallman first systematically described, in Finnish infants, a familial disease characterized by severe proteinuria and edema presenting within weeks to months after birth. Hallman named it 'congenital nephrotic syndrome of the Finnish type (CNF)' and reported that it showed an autosomal recessive mode of inheritance. In Finland, the incidence of this disease is about 1–2 per 10,000 births, the highest in the world, which was found to be due to the founder effect and genetic bottleneck in the Finnish population.

Initially, because kidney biopsy often showed no clear structural abnormalities of the glomeruli on light microscopy, the histologic classification 'minimal change' was used. However, with the introduction of electron microscopy, extensive fusion and effacement of foot processes was identified, and this was found to be directly linked to the breakdown of the protein barrier of the glomerular filtration barrier. In the 1970s–80s, various cases of congenital nephrotic syndrome were reported around the world, and genetic heterogeneity gradually began to be recognized.

The most groundbreaking advance came in 1998 when Kestilä et al. cloned the NPHS1 gene and named the protein it encodes 'nephrin'. Nephrin is a constituent protein of the slit diaphragm of the glomerular filtration barrier and plays a key role in the connecting structure between the processes of glomerular podocytes. In the same year, podocin, encoded by the NPHS2 gene, was also identified, and subsequently variants in various genes such as WT1, LAMB2, and PLCE1 were reported as causes of congenital nephrotic syndrome. This established that congenital nephrotic syndrome is not a single disease but a genetically heterogeneous group of diseases.

Minimal change congenital nephrotic syndrome (N04.0) refers to the form in which the glomerular tissue shows no specific findings on light microscopy and immunofluorescence but foot process effacement is observed on electron microscopy; it shares the same histologic findings as acquired minimal change nephrotic syndrome but is fundamentally distinct in age of onset, genetic background, and treatment response. With advances in molecular genetics, a considerable portion of congenital nephrotic syndrome previously classified as 'idiopathic' or 'of unknown cause' can now be explained by specific gene variants, which is being used directly to establish personalized treatment strategies.

In Korea, the genetic diagnostic yield for congenital nephrotic syndrome has improved with the introduction of gene panel testing since the 2000s, and awareness of and access to treatment for this disease in pediatric nephrology have improved. Case accumulation and multicenter studies are being conducted, centered on the Korean Society of Pediatric Nephrology, and a system of medical cost support through rare disease Special Copayment Reduction registration is in place.

2. Causes

Minimal change congenital nephrotic syndrome is a hereditary kidney disease caused by pathogenic variants in genes encoding constituent proteins of the glomerular filtration barrier. The glomerular filtration barrier consists of three layers: the endothelium, the glomerular basement membrane (GBM), and the podocytes, and in particular the slit diaphragm between podocyte processes acts as the key barrier to protein filtration.

The most important causative gene is NPHS1 (nephrin), located on the long arm of chromosome 19 (19q13.12), which encodes nephrin, the major constituent protein of the slit diaphragm. About 90% of congenital nephrotic syndrome of the Finnish type is due to NPHS1 variants, and in Finland two variants, p.Leu41ArgfsTer9 (Fin major) and p.Arg1109Ter (Fin minor), account for about 98% of all Finnish-type cases. These two variants are products of the founder effect in the Finnish population, while diverse NPHS1 variants have been reported in non-Finnish populations.

NPHS2 (podocin) is located on the long arm of chromosome 1 (1q25.2) and encodes podocin. Podocin binds directly to nephrin and stabilizes the slit diaphragm complex, and NPHS2 variants are the most common cause of nephrotic syndrome presenting in infancy and early childhood. The NPHS2 p.R138Q variant is common in patients of European descent, and different phenotypes appear with compound heterozygous variants (in combination with p.R229Q).

WT1 (Wilms tumor suppressor 1) is located on the short arm of chromosome 11 (11p13) and, as a transcription factor, is essential for podocyte differentiation. WT1 variants present with diverse phenotypes, including Denys-Drash syndrome (nephrotic syndrome + male pseudohermaphroditism + Wilms tumor), Frasier syndrome, and isolated nephrotic syndrome. LAMB2 (laminin β2) encodes laminin β2, a component of the GBM, and LAMB2 variants are associated with Pierson syndrome (microcoria + nephrotic syndrome). PLCE1 (phospholipase C epsilon 1) variants may present with mesangial proliferation or as the minimal change type.

Histologically, the minimal change type (N04.0) shows no clear abnormalities of the glomeruli, tubules, or interstitium on light microscopy, with extensive foot process effacement identified only on electron microscopy. The histologic findings are identical to those of acquired minimal change nephrotic syndrome, but the congenital form is essentially distinct in that its mechanism is an abnormality of slit diaphragm structural proteins rather than an abnormal T-cell immune response. NPHS1 or NPHS2 variants are identified in some cases, but the genetic cause still remains unidentified in a considerable portion of minimal change congenital nephrotic syndrome, so further research is needed.

3. Genetics

Most congenital nephrotic syndromes, including minimal change congenital nephrotic syndrome, follow an autosomal recessive (AR) mode of inheritance. When each parent is a carrier (heterozygous) of a pathogenic variant, the probability that a child has homozygous or compound heterozygous variants is 25%. Therefore, parental consanguinity markedly increases the risk.

The modes of inheritance of the major causative genes are summarized as follows. NPHS1: autosomal recessive, 19q13.12, 29 exons, coding sequence 3,762 bp, nephrin protein of 1,241 amino acids. NPHS2: autosomal recessive, 1q25.2, 8 exons, coding sequence 1,146 bp, podocin protein of 383 amino acids. WT1: autosomal dominant (rarely sporadic de novo variants), 11p13, 10 exons, zinc finger transcription factor. LAMB2: autosomal recessive, 3p21.31, 30 exons. PLCE1: autosomal recessive, 10q23.33, 33 exons.

Genotype-phenotype correlations are well established for some genes. The Finnish founder variants of NPHS1 (Fin major/Fin minor homozygous) are associated with a severe phenotype with extreme proteinuria within weeks after birth, placental enlargement, and stillbirth or early renal failure. In contrast, with non-Finnish NPHS1 variants (including missense variants), age of onset and severity vary. The NPHS2 p.R229Q variant produces a phenotype only when compound heterozygous with another NPHS2 variant and does not cause disease when heterozygous alone.

Next-generation sequencing (NGS)-based nephrotic syndrome gene panels (nephropathy gene panels) or whole exome sequencing (WES) have become the standard for genetic diagnosis. Pediatric nephrotic syndrome cohort studies report that a genetic cause can be identified in about 80–90% of nephrotic syndrome presenting before 6 months of age. Genetic diagnosis is used directly to predict response to steroid treatment (high likelihood of steroid resistance when a gene variant is confirmed), assess post-transplant recurrence risk, and for family counseling and carrier testing.

When carrier parents have been identified, prenatal diagnosis is performed by analysis of the familial variant in fetal DNA obtained by chorionic villus sampling (11–14 weeks) or amniocentesis (15–20 weeks). Preimplantation genetic testing (PGT) is also offered as an option and is considered especially in high-risk families (those already with an affected child). Comprehensive genetic counseling together with carrier testing is recommended for first-degree relatives of all patients with congenital nephrotic syndrome.

4. General epidemiology

The overall incidence of congenital nephrotic syndrome is estimated at about 1–2 per 10,000 births, but there are considerable differences by country and ethnicity. In Finland, due to the high carrier frequency of NPHS1 founder variants, the incidence is high at about 1 per 8,200 births, and congenital nephrotic syndrome of the Finnish type has long been studied as a rare disease characteristic of Finland.

Minimal change (N04.0) congenital nephrotic syndrome accounts for a minority of all congenital nephrotic syndromes, and accurate prevalence data are limited. This is because congenital nephrotic syndrome is classified into various ICD subcodes according to histologic findings, and it is difficult to distinguish the minimal change type from other subtypes without electron microscopy. By age, onset within 3 months after birth is defined as 'congenital', but some authors include onset within 1 year after birth. No sex difference in occurrence has been reported, and it occurs in all ethnic groups, but the frequency of specific variants differs by ethnicity.

In Korea, accurate prevalence statistics for minimal change congenital nephrotic syndrome are not compiled separately, but data are continuously being accumulated, centered on cases with confirmed heredity among all pediatric nephrotic syndrome. The number of patients registered under code N04.0 through the Health Insurance Review & Assessment Service (HIRA) and the rare disease registration system is estimated at several dozen to several hundred, and in Korea it is registered and managed as a rare disease falling under Special Copayment Reduction code V263. Congenital nephrotic syndrome overall is often associated with placental enlargement, preterm birth, and low birth weight, and placental enlargement identified on prenatal ultrasound can be a diagnostic clue.

Because of genetic heterogeneity, single-gene-based epidemiological data are incomplete, and accumulation of large-scale epidemiological data through international congenital nephrotic syndrome registries (e.g., PodoNet, EuroPOD) will be important in the future. In non-Finnish countries, NPHS2 variants are found more often in patients of European and Middle Eastern descent, and in Asian patients, ethnic differences in the frequency of WT1 and PLCE1 variants besides NPHS1 and NPHS2 have been reported, so research on the variant spectrum specific to Koreans is needed.

5. Pathophysiology

The glomerular filtration barrier is a sophisticated structure that prevents plasma proteins from leaking into the urine, consisting of three layers: the endothelial fenestrae, the glomerular basement membrane (GBM), and the podocyte slit diaphragm. Of these, the slit diaphragm is the final barrier to protein filtration, in which proteins such as nephrin, podocin, CD2AP, ZO-1, and α-actinin-4 form a highly organized complex.

The core mechanism in minimal change congenital nephrotic syndrome is a structural abnormality of the slit diaphragm complex. Nephrin deficiency or dysfunction due to NPHS1 variants disrupts the zipper-like structure of the slit diaphragm, causing loss of its molecular barrier function. Beyond being a simple structural protein, nephrin also functions as a signaling protein relaying podocyte survival signals (PI3K/Akt pathway, Rho GTPase activation), and nephrin deficiency promotes podocyte apoptosis and foot process effacement. Podocin abnormalities due to NPHS2 variants interfere with binding to nephrin and reduce cell-surface expression of nephrin, producing the same result.

Foot process effacement results from rearrangement of the podocyte cytoskeleton, particularly the breakdown of F-actin structures. Abnormal slit diaphragm signaling interferes with Rho GTPase (Rac1, Cdc42) activity and reduces the stability of the synaptopodin-nephrin-podocin complex, resulting in microvillous transformation and foot process fusion. As a result, medium-molecular-weight proteins including albumin pass through the glomerular filtration barrier, producing massive proteinuria.

Massive proteinuria causes hypoalbuminemia, and the resulting decrease in colloid osmotic pressure and sodium retention cause generalized edema and ascites. Hypoalbuminemia also causes hyperlipidemia and lipiduria through abnormal lipoprotein metabolism, which is associated with an increased risk of thrombosis. Persistent proteinuria and hypoalbuminemia lead to malnutrition, susceptibility to infection due to loss of immunoglobulins, and increased thrombotic/bleeding risk due to loss of coagulation factors, resulting in systemic complications.

6. Symptoms

The most prominent clinical symptoms of minimal change congenital nephrotic syndrome are massive proteinuria and generalized edema presenting within a few weeks to 3 months after birth. This period is the neonatal period or early infancy, and symptoms progress rapidly, requiring early active medical intervention.

Edema is the earliest and most prominent symptom. Initially, periorbital edema appears, then it spreads to the limbs, scrotum or labia, and abdomen. Ascites causes abdominal distension and can lead to respiratory distress, feeding difficulties, and vomiting. Pleural effusion worsens respiratory distress, and pericardial effusion rarely occurs. Edema is the combined result of hypoalbuminemia and sodium and water retention.

Proteinuria is nephrotic-range proteinuria defined as a urine protein/creatinine ratio of 2.0 mg/mg or higher (infants) or 40 mg/m²/hr or higher. The urine may appear foamy or cloudy, but this is not easy to recognize visually in infants. Hypoalbuminemia (serum albumin < 2.5 g/dL, severe < 1.5 g/dL) is accompanied by hyperlipidemia and lipiduria.

Susceptibility to infection is a major complication; urinary loss of immunoglobulins (especially IgG) and complement factors greatly increases the risk of bacterial peritonitis, sepsis, and pneumonia due to pneumococci and gram-negative bacteria. Thrombosis occurs due to loss of anticoagulant factors (antithrombin III, proteins C and S) and increased procoagulant factors (fibrinogen, factors V and VIII), and renal vein thrombosis and pulmonary embolism are important complications. Growth retardation and malnutrition are also prominent because of protein loss, decreased appetite, and malabsorption due to gastrointestinal edema.

In congenital nephrotic syndrome of the Finnish type (mainly NPHS1 variants), placental enlargement (placenta/fetal weight ratio > 25%) can characteristically be identified during pregnancy, and elevated α-fetoprotein in the amniotic fluid is observed even at the fetal stage. Preterm birth and low birth weight are common, and edema and proteinuria are evident from immediately after birth. This subtype does not respond at all to steroids and immunosuppressants and progresses to end-stage renal disease within 2–3 years without aggressive albumin replacement and nutritional support.

7. Signs

The main signs observed on physical examination are the distribution and degree of edema, nutritional status, and signs of infection. Facial edema (especially prominent in the morning), pitting edema of the limbs, and ascites identified by abdominal distension and a fluid thrill on palpation are characteristic. Scrotal or labial edema may be prominent in infants, and when edema is severe, the skin becomes taut and shiny.

Among vital signs, blood pressure may initially be low due to decreased intravascular volume from hypoproteinemia, but may become normal or high as sodium retention progresses. Respiratory assessment may reveal decreased breath sounds due to pleural effusion and dullness on chest percussion. Abdominal examination shows abdominal distension and shiny skin due to ascites.

Laboratory findings: positive urine protein (4+ dipstick), markedly elevated 24-hour urine protein or urine protein/creatinine ratio (UPCR), elevated urine ovalbumin or α1-microglobulin. Serum albumin < 2.5 g/dL (severe < 1.5 g/dL). Elevated total cholesterol, LDL cholesterol, and triglycerides, and decreased HDL (hyperlipidemia). Serum creatinine is normal initially but rises with progression. Serum sodium is normal or shows dilutional hyponatremia. CBC shows hemoconcentration or anemia. Coagulation tests show shortened PT/APTT (hypercoagulable state) or prolongation (with severe deficiency). Decreased antithrombin III and protein C and S levels. Normal complement (C3, C4) (a finding distinguishing it from the membranoproliferative type).

Kidney biopsy findings: on light microscopy, normal glomerular structure or mild mesangial proliferation, with minimal tubular changes. No immune deposits on immunofluorescence (negative). On electron microscopy, extensive effacement of podocyte foot processes (global effacement), hypertrophy of podocyte cell bodies, and loss of slit diaphragms are characteristic. GBM abnormalities are absent or minimal.

Growth and development assessment may show poor weight gain, retarded linear (height) growth, and retarded head circumference growth, and protein loss and the chronic disease state adversely affect overall development. In Pierson syndrome (LAMB2 variants), microcoria appears as a characteristic ophthalmologic sign.

8. Screening

Universal newborn screening for minimal change congenital nephrotic syndrome is not currently performed. This is because it is an uncommon rare disease, the cost-effectiveness of universal screening is low, and genetic heterogeneity makes screening based on a single biochemical marker difficult. However, a systematic screening approach is needed for high-risk groups with a family history and clinically suspected cases.

Prenatal screening: elevated maternal serum α-fetoprotein (AFP) may be observed in congenital nephrotic syndrome of the Finnish type (NPHS1 variants), and when abnormal findings are identified on prenatal AFP screening, congenital nephrotic syndrome should be included in the differential diagnosis. Placental enlargement (placental weight/fetal weight ratio > 25%) can be suspected on fetal ultrasound, and in families with NPHS1 variants, prenatal genetic testing during pregnancy should be planned in advance.

Newborn screening within high-risk families: in newborns from families with an affected sibling, or when the parents' carrier status has been confirmed (autosomal recessive families), urine protein testing (urine dipstick or UPCR), serum albumin, and serum creatinine are measured immediately after birth. Molecular genetic testing (familial variant analysis) is performed as the top priority to confirm early whether congenital nephrotic syndrome has developed. When a positive result is predicted, it is recommended that a plan for early intervention by the neonatal intensive care unit or a pediatric nephrology team be established prenatally.

Screening based on clinical suspicion: even without a family history, congenital nephrotic syndrome is immediately suspected in newborns and infants with edema, ascites, and hypoalbuminemia presenting within 3 months after birth, and urine protein testing and serum albumin measurement are performed. Immediate testing after birth is also recommended when placental enlargement was identified during pregnancy. In newborns with generalized edema, basic tests to differentiate congenital nephrotic syndrome from congenital heart disease, congenital lymphedema, hemolytic disease of the newborn, sepsis, and the like are performed concurrently.

Gene panel testing: when congenital nephrotic syndrome is suspected from urine protein testing and serum albumin, the current standard is early hereditary nephrotic syndrome gene panel testing including NPHS1, NPHS2, WT1, LAMB2, and PLCE1. If the panel is negative, expansion to whole exome sequencing (WES) or whole genome sequencing (WGS) is recommended. Genetic diagnosis is used directly to judge the need for kidney biopsy, plan treatment, and predict prognosis.

9. Diagnosis

The diagnosis of minimal change congenital nephrotic syndrome rests on three pillars: fulfilling the clinical criteria, histopathologic confirmation, and genetic analysis. Nephrotic syndrome presenting within 3 months after birth (1 year by some criteria) is the prerequisite for the diagnosis.

Clinical diagnostic criteria: nephrotic syndrome is diagnosed when the following 4 are met: ① nephrotic-range proteinuria: urine protein/creatinine ratio (UPCR) ≥ 2.0 mg/mg (adult criterion > 3.5 g/day) or 24-hour urine protein > 40 mg/m²/hr, ② hypoalbuminemia: serum albumin < 2.5 g/dL, ③ edema, ④ hyperlipidemia (lipiduria is supportive). If onset is within 3 months after birth, it is classified as 'congenital'.

Kidney biopsy: kidney biopsy is performed when the genetic diagnosis has not been confirmed or to decide on a treatment strategy. Light microscopy, immunofluorescence, and electron microscopy are performed simultaneously, and for the N04.0 classification, absence of specific glomerular findings on light microscopy, absence of immune complex deposits on immunofluorescence, and extensive foot process effacement on electron microscopy must be confirmed. Because kidney biopsy in infants involves technical difficulties and a risk of bleeding, it is performed by a pediatric nephrology team, and special care is also required in specimen processing.

Genetic testing: for early confirmation of congenital nephrotic syndrome and treatment planning, current practice guidelines strongly recommend gene panel testing at the same time as clinical diagnosis. The test panel should include at least NPHS1, NPHS2, WT1, LAMB2, and PLCE1, and expanded panels (including INF2, ADCK4, COQ6, PTPRO, etc.) increase diagnostic yield. If the gene panel is negative, proceed to WES or WGS. Variant interpretation classifies variants as pathogenic, likely pathogenic, or VUS (uncertain significance) according to the ACMG guidelines, and for VUS, functional studies or segregation analysis are recommended.

Differential diagnosis: congenital nephrotic syndrome must be differentiated from ① acquired nephrotic syndrome (onset in infants or children, not hereditary), ② neonatal lupus nephritis (transfer of maternal anti-Ro/La antibodies), ③ congenital syphilis, congenital toxoplasmosis, and congenital cytomegalovirus infection (infectious congenital nephrotic syndrome), and ④ other causes of edema in newborns or infants (congenital heart disease, lymphedema, hemolytic disease). Infectious causes are excluded by TORCH testing of the mother and newborn.

WT1-related evaluation: when a WT1 variant is confirmed, genital examination (abnormal external genital development), abdominal ultrasound (Wilms tumor surveillance), karyotyping, and evaluation for disorders of sex development are performed to evaluate for Denys-Drash or Frasier syndrome.

10. Treatment

Treatment of minimal change congenital nephrotic syndrome has evolved toward predicting response to steroids and immunosuppressants according to the type of gene variant and establishing individualized strategies. Patients with confirmed NPHS1 or NPHS2 variants have no immune-mediated mechanism and therefore do not respond to steroids and immunosuppressants, but in patients with no identified variant or a VUS, a diagnostic treatment trial is considered.

Steroid treatment: in congenital nephrotic syndrome with a confirmed gene variant, steroid treatment is unnecessary (no response). In patients with no identified variant, the response is evaluated after 4 weeks of prednisolone 60 mg/m²/day (or 2 mg/kg/day, maximum 60 mg). If steroid responsiveness (SSNS, steroid-sensitive nephrotic syndrome) is confirmed, the standard pediatric nephrotic syndrome treatment protocol is followed. If steroid resistance (SRNS) is confirmed, the patient moves on to second-line immunosuppressant treatment or reassessment of genetic testing.

Cyclosporine/tacrolimus: there are reports that calcineurin inhibitors (CNI) can partially reduce proteinuria in patients with NPHS2 variants or a few NPHS1 variants, but it must be considered that they are not a definitive treatment and carry long-term nephrotoxicity. Immunosuppressants such as cyclophosphamide and mycophenolate mofetil (MMF) are used in SRNS in combination with CNIs or alone.

ACE inhibitors/ARBs: renin-angiotensin inhibitors contribute to preservation of renal function by lowering intraglomerular pressure and reducing proteinuria. There are reports that combination with indomethacin is temporarily useful in reducing proteinuria in congenital nephrotic syndrome of the Finnish type.

Adjunctive and supportive care: intravenous albumin (20% albumin, 0.5–1 g/kg) is combined with a diuretic (furosemide) to control severe edema and maintain circulating blood volume. Nutritional support compensates for protein loss with increased dietary protein intake, a high-calorie diet, and, if needed, tube feeding or parenteral nutrition. Prophylactic antibiotics (penicillin) are used to prevent pneumococcal infection, and pneumococcal and varicella vaccination is recommended. To prevent thrombosis, anticoagulation therapy (heparin or warfarin) is considered in high-risk situations (serum albumin < 2.0 g/dL, reduced mobility).

Kidney transplantation: the definitive treatment of congenital nephrotic syndrome is kidney transplantation. It is generally recommended that transplantation be performed at a body weight of 8–10 kg or more (about 2–3 years of age). As pre-transplant preparation, nephrectomy (unilateral or bilateral nephrectomy) to control proteinuria is considered in some patients. In patients with NPHS1 variants, recurrent nephrotic syndrome due to anti-nephrin antibodies (de novo antibody-mediated rejection or recurrence) has rarely been reported after transplantation, which is related to the type of NPHS1 variant (when no nephrin at all is expressed, an immune response is possible upon antigen exposure). Post-transplant immunosuppressive therapy follows standard pediatric kidney transplantation protocols.

11. Prognosis

The prognosis of minimal change congenital nephrotic syndrome varies greatly with the type of gene variant, the timing of diagnosis and treatment, and whether complications occur. Overall, congenital nephrotic syndrome of the Finnish type due to NPHS1 variants has the most severe prognosis, progressing to end-stage renal disease within 2–3 years without treatment.

Renal prognosis: most patients with congenital nephrotic syndrome progress to end-stage renal disease (ESRD) within childhood and require renal replacement therapy (dialysis or kidney transplantation). In patients with NPHS1 variants, aggressive conservative treatment (albumin replacement, nutritional support, suppression of proteinuria) can increase survival until they reach a body weight suitable for kidney transplantation. Patients with NPHS2 variants progress to ESRD at various times from childhood to adulthood depending on age of onset and variant type. The 5-year survival after kidney transplantation is reported at 80–90%, similar to general pediatric kidney transplantation.

Post-transplant prognosis: in patients with NPHS1 variants, recurrent nephrotic syndrome due to anti-nephrin antibodies may rarely (about 25%) occur after transplantation, which can affect graft function. Post-transplant recurrence is very rare in patients with NPHS2 variants. In WT1-related patients (Denys-Drash/Frasier syndrome), Wilms tumor surveillance continues to be necessary even after transplantation.

Development and quality of life: there are reports that in patients who receive early kidney transplantation, height growth, neurodevelopment, and school life mostly recover to normal levels. However, chronic kidney disease, immunosuppression, repeated hospitalizations, and school absences can adversely affect psychosocial development, and psychosocial support for patients and families is important. The more severe the pre-transplant malnutrition and growth retardation, the more limited the degree of post-transplant catch-up growth may be.

Causes of death: infection (pneumococcal sepsis, peritonitis) and thrombosis (renal vein thrombosis, pulmonary embolism) are the main causes of death in congenital nephrotic syndrome. Prophylactic antibiotics, vaccination, monitoring of albumin levels, and anticoagulation therapy contribute to reduced mortality. In the modern intensive pediatric nephrology care system, survival until reaching a body weight suitable for transplantation has improved greatly compared with the past.

12. Prevention

Because congenital nephrotic syndrome is a hereditary disease, primary prevention consists mainly of preventing the birth of affected children through genetic counseling and prenatal/preimplantation genetic testing. In patients already diagnosed, prevention of complications (infection, thrombosis, malnutrition) is the key secondary and tertiary prevention strategy.

Genetic counseling: for parents with an affected child or when carrier status has been confirmed, genetic counseling accurately conveys the recurrence risk in the next pregnancy (25% for AR inheritance) and offers options for prenatal diagnosis and preimplantation genetic testing. Genetic counseling is non-directive and supports the parents' autonomous decisions.

Prenatal diagnosis: when the parental variants have been identified, whether the fetus is affected is confirmed by fetal DNA analysis by chorionic villus sampling (11–14 weeks of pregnancy) or amniocentesis (15–20 weeks of pregnancy). In families at risk for congenital nephrotic syndrome of the Finnish type (NPHS1), maternal serum AFP monitoring is used as an adjunct. Decisions to continue or terminate the pregnancy based on prenatal diagnostic results are made individually according to the parents' values and the legal environment.

Preimplantation genetic testing (PGT): preimplantation genetic testing combined with in vitro fertilization prevents implantation of affected embryos, so the birth of an affected child can be prevented without termination of pregnancy. It is technically possible when the parental variants have been clearly identified and is also performed at some institutions in Korea.

Prevention of complications: in diagnosed patients, pneumococcal vaccination (PCV13 and PPSV23), annual influenza vaccination, and completion of hepatitis B vaccination are maintained. Prophylactic penicillin V (6 months to 5 years) contributes to reduced mortality during the period of high risk for pneumococcal infection. In high-risk thrombotic states (albumin < 2.0 g/dL), anticoagulation therapy is considered preemptively. Close cooperation with the nutrition team maintains adequate protein and calorie supply so that the patient can reach a body weight and developmental status suitable for transplantation.


13. References

  1. Kestilä M, Männikkö M, Holmberg C, et al. Congenital nephrotic syndrome of the Finnish type maps to the long arm of chromosome 19. Am J Hum Genet. 1994;54(5):757-764. PMID: 8178815.
  2. Kestilä M, Lenkkeri U, Männikkö M, et al. Positionally cloned gene for a novel glomerular protein — nephrin — is mutated in congenital nephrotic syndrome. Mol Cell. 1998;1(4):575-582. DOI: 10.1016/S1097-2765(00)80057-X. PMID: 9660941.
  3. Boute N, Gribouval O, Roselli S, et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet. 2000;24(4):349-354. DOI: 10.1038/74166. PMID: 10742096.
  4. Hinkes B, Wiggins RC, Gbadegesin R, et al. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet. 2006;38(12):1397-1405. DOI: 10.1038/ng1918. PMID: 17086183.
  5. Holmberg C, Jalanko H. Congenital nephrotic syndrome and recurrence of proteinuria after renal transplantation. Pediatr Nephrol. 2014;29(12):2309-2317. DOI: 10.1007/s00467-013-2459-8. PMID: 23793713.
  6. Machuca E, Benoit G, Antignac C. Genetics of nephrotic syndrome: connecting molecular genetics to podocyte physiology. Hum Mol Genet. 2009;18(R2):R185-R194. DOI: 10.1093/hmg/ddp328. PMID: 19808799.
  7. Trautmann A, Vivarelli M, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020;35(8):1529-1561. DOI: 10.1007/s00467-020-04519-1. PMID: 32382828.
  8. Sadowski CE, Lovric S, Ashraf S, et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2015;26(6):1279-1289. DOI: 10.1681/ASN.2014050489. PMID: 25349199.
  9. Jalanko H. Congenital nephrotic syndrome. Pediatr Nephrol. 2009;24(11):2121-2128. DOI: 10.1007/s00467-007-0633-9. PMID: 17968594.
  10. Kim JH, Han KH, Lee JM, et al. Genetic and clinical characteristics of childhood-onset nephrotic syndrome in Korea. J Korean Med Sci. 2019;34(6):e55. DOI: 10.3346/jkms.2019.34.e55. PMID: 30799572.